Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Vasundhara Rasayans Limited specializes in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), primarily serving the Indian market with a growing export footprint in Europe and North America. The company leverages its low-cost manufacturing capabilities and strong relationships with local suppliers to maintain a competitive edge in pricing and quality.
VRL generates revenue through the manufacture and sale of pharmaceutical intermediates and APIs, benefiting from strong pricing power due to its established reputation for quality and compliance with regulatory standards. The company has a competitive advantage through its low debt levels and high gross margins, allowing it to invest in R&D and expand its product offerings.
Regulatory approvals for new APIs in key markets
Changes in raw material costs impacting margins
Expansion of export capabilities to new regions
Market demand for generic pharmaceuticals
Regulatory changes affecting pharmaceutical manufacturing standards
Technological disruption in drug development processes
Emergence of low-cost competitors in the API market
Potential pricing pressures from larger pharmaceutical companies
Limited cash flow generation impacting investment in growth opportunities
Potential currency risk from international sales
moderate - The pharmaceutical sector tends to be resilient during economic downturns, but demand for certain non-essential drugs can be affected by consumer spending.
Minimal impact as the company has low debt levels; however, rising rates could affect overall investment sentiment in the healthcare sector.
minimal - The company operates with a low debt-to-equity ratio, reducing reliance on credit markets.
growth - Investors may be drawn to the company's potential for revenue growth through expanding its product portfolio and market reach.
moderate - The stock has shown some volatility, particularly with recent performance fluctuations.
